ArticleVirologica Sinica2026
Two orthobunyaviruses: OYAV and EBIV co-opt the AhR-CYP1A1 axis to suppress type I interferon responses.
Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The type I interferon (IFN-I) system serves as a frontline defense against viral infection, yet how orthobunyaviruses counteract this pathway remains poorly defined. Here, we identify cytochrome P450 1A1 (CYP1A1) as a crucial host factor promoting infection by two emerging orthobunyaviruses-Oya virus (OYAV) and Ebinur Lake virus (EBIV). Transcriptomic and functional analyses demonstrate that CYP1A1 overexpression enhances viral RNA synthesis, whereas its CRISPR-Cas9-mediated knockout attenuates infection. Mechanistically, OYAV and EBIV activate the aryl hydrocarbon receptor (AhR), driving its nuclear translocation and subsequent upregulation of CYP1A1. Deficiency of CYP1A1 potentiates IFN-β production and interferon-stimulated gene (ISG) expression, while its overexpression suppressed antiviral signaling, revealing an immunomodulatory role that is distinct from its canonical metabolic function. Collectively, this work defines the AhR-CYP1A1 axis as a conserved immune-evasion module exploited by emerging orthobunyaviruses and highlights the innate immune pathway as a potential therapeutic target against these emerging threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.